MedTrace Logo

ch14.18/CHO Bridging Study

NCT01704872 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-10-22

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, pharmacokinetic and activity profiles of the ch14.18 antibody produced in cells of hamster origin (ch14.18/CHO).

Conditions

Interventions

DRUG

ch14.18/CHO

Sponsors & Collaborators

  • St. Anna Children's Hospital, Vienna

    collaborator UNKNOWN

  • Charite University, Berlin, Germany

    collaborator OTHER

  • Istituto Giannina Gaslini

    collaborator OTHER

  • St. Anna Kinderkrebsforschung

    lead OTHER

Principal Investigators

  • Holger Lode, MD · Charite Children's Hospital

  • Ruth Ladenstein, MD · St. Anna Kinderkrebsforschung

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2006-02-28
Completion
2012-03-31

Countries

  • Austria
  • Germany
  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01704872 on ClinicalTrials.gov